Verheul HM - Search Results

1

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.

Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R. Verheul HM, et al. Clin Cancer Res. 2007 Jul 15;13(14):4201-8. doi: 10.1158/1078-0432.CCR-06-2553. Clin Cancer Res. 2007. PMID: 17634549

2

Platelet: transporter of vascular endothelial growth factor.

Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Verheul HM, et al. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90. Clin Cancer Res. 1997. PMID: 9815613

3

Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.

Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, Pinedo HM. Verheul HM, et al. Clin Cancer Res. 2000 Jan;6(1):166-71. Clin Cancer Res. 2000. PMID: 10656446

4

The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.

Verheul HM, Pinedo HM. Verheul HM, et al. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S80-4. doi: 10.3816/cbc.2000.s.015. Clin Breast Cancer. 2000. PMID: 11970755 Review.

5

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Qian DZ, et al. Among authors: verheul hm. Cancer Res. 2006 Sep 1;66(17):8814-21. doi: 10.1158/0008-5472.CAN-05-4598. Cancer Res. 2006. PMID: 16951198

6

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.

Verheul HM, Qian DZ, Carducci MA, Pili R. Verheul HM, et al. Cancer Chemother Pharmacol. 2007 Aug;60(3):329-39. doi: 10.1007/s00280-006-0379-2. Epub 2007 Jan 26. Cancer Chemother Pharmacol. 2007. PMID: 17256134

7

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R. Kato Y, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4538-46. doi: 10.1158/1078-0432.CCR-07-0014. Clin Cancer Res. 2007. PMID: 17671140

8

Platelets take up the monoclonal antibody bevacizumab.

Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. Verheul HM, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5341-7. doi: 10.1158/1078-0432.CCR-07-0847. Epub 2007 Sep 12. Clin Cancer Res. 2007. PMID: 17855648

9

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. Verheul HM, et al. Clin Cancer Res. 2008 Jun 1;14(11):3589-97. doi: 10.1158/1078-0432.CCR-07-4306. Clin Cancer Res. 2008. PMID: 18519793

10

A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.

Kortenhorst MS, Zahurak M, Shabbeer S, Kachhap S, Galloway N, Parmigiani G, Verheul HM, Carducci MA. Kortenhorst MS, et al. Among authors: verheul hm. Clin Cancer Res. 2008 Nov 1;14(21):6886-94. doi: 10.1158/1078-0432.CCR-08-0119. Clin Cancer Res. 2008. PMID: 18980983 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

348 results

Search Page

Filters